Key Drivers
- High gross margin
- Heavy leverage
- Quarterly volatility
AIAI Summary
MannKind's shift to a hybrid commercial model—with accelerating Afrezza and FUROSCIX sales—turns the thesis from a single-trial binary into a commercialization-and-regulatory execution story where sustained revenue and payer uptake drive value. Actionable focus: monitor the May 29 pediatric Afrezza PDUFA, FUROSCIX injector approvals/reimbursement, and quarterly cash flow/refinancing needs, because positive outcomes can materially re-rate shares while misses or cash shortfalls likely force dilution.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High gross margin
- •Heavy leverage
- •Quarterly volatility
MNKD shows strong gross margins and FY cash generation but acute quarterly earnings volatility and a precarious balance sheet with heavy long-term debt and negative equity.
Price Behavior
Key Price Behavior Insights:
- •Strong downtrend
- •Below moving average
- •Clustered consolidation
MNKD plunged ~55% last month to $2.47 and sits well below the ~$3.23 last-month moving average, signaling clear downside momentum with near-term clustering at $2.6–$2.9 as a potential pivot but major resistance near $5.5.
Rapid collapse from ~$5.5 to low-$2s last month indicating high volatility
Sentiment & News
Key News Insights:
- •Revenue strength
- •Debt reduction
- •Upcoming PDUFA
MannKind showed strong revenue and Furoscix sales growth but missed EPS expectations, spurred a stock pullback and downgrade, cleaned up convertible debt, and faces a near-term Afrezza pediatric PDUFA on 2026-05-29.
Positive top-line trends and debt cleanup improve medium-term commercial prospects, but near-term share performance will hinge on the Afrezza pediatric PDUFA and path to profitability
Similar Companies in Healthcare
Other companies in the same sector with AI ratings